翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 歐康維視生物 (「本公司」) （於開曼群島註冊成立的有限公司） 呈交日期： 2025年8月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01477 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年3月31日 狀態: 重新提交 呈交日期: 2025年8月18日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01477 | 說明 | 普通股 | | | | | | | | 法定/註冊股份數目 | | | 面值 | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | 0.00001 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 歐康維視生 ...

致：香港交易及結算所有限公司 公司名稱: 歐康維視生物 (「本公司」) （於開曼群島註冊成立的有限公司） 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年2月28日 狀態: 重新提交 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01477 | 說明 普通股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | 0.00001 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | 0.00001 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF3 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 公司名稱： 歐康維視生物 (「本公司」) （於開曼群島註冊成立的有限公司） 呈交日期： 2025年8月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01477 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通知的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通知全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 Ocumension Therapeutics 歐康維視生物 （於開曼群島註冊成立的有限責任公司） （股份代號：1477） 董事會會議通知 歐康維視生物（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於二零二五年 八月二十一日（星期四）舉行董事會會議，藉以（其中包括）考慮及批准本公司及其 附屬公司截至二零二五年六月三十日止六個月之中期業績及其發佈，並考慮建議 派付中期股息（如有）。 歐康維視生物 Lian Yong CHEN博士 主席兼非執行董事 香港，二零二五年八月十一日 截至本通知日期，董事會包括執行董事Ye LIU先生及胡兆鵬博士，非執行董事 Lian Yong CHEN博士、曹彥凌先生及謝沁博士，及獨立非執行董事胡定旭先生、 黃翼然先生及張振宇先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 歐康維視生物 (「本公司」) （於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月5日 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01477 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 813,835,014 | | 20,945,500 | | 834,780,514 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 813,835,014 | | 20,945,500 | | 834,780,514 | 第 2 頁 共 10 ...

Core Insights - Foreign public funds have shown strong performance in Q2, with a focus on structural opportunities in the Chinese market, particularly in artificial intelligence, innovative pharmaceuticals, and high-dividend assets [1][2][3] Group 1: Fund Performance - Several foreign public equity products achieved notable returns in Q2, with the Robeco China Healthcare Equity Fund leading at a 28.51% increase in net value [1] - BlackRock's Advanced Manufacturing Fund and Fidelity's Dividend Growth Fund reported net value increases of 21.83% and 13.64%, respectively [1] Group 2: Investment Strategies - Robeco emphasized a multi-dimensional evaluation of companies in the innovative sector, focusing on quality, talent, R&D investment, and clinical data to select high-potential firms [1] - BlackRock's fund manager highlighted a strategic focus on artificial intelligence and technology sectors, achieving significant excess returns [2] - Fidelity's managers noted strong performance in traditional dividend sectors, attracting risk-averse capital due to low valuations and high dividend certainty [2] Group 3: Future Outlook - Fund managers expressed optimism about the attractiveness of A-share valuations, supported by policy backing and positive industry trends, indicating ongoing structural opportunities [2] - Future investment will continue to prioritize high-quality technology assets and sectors with concentrated distribution, such as TMT, machinery, pharmaceuticals, and chemicals [3] - The Chinese pharmaceutical industry is expected to enhance its global competitiveness, with a clear trend towards international expansion in innovative drugs and medical devices [3]

Group 1 - China's Q2 GDP growth reached 5.2%, exceeding expectations, leading to a rally in Hong Kong stocks [1] - The Hang Seng Technology Index surged by 2.8%, while the Hang Seng Index and the National Enterprises Index rose by 1.6% and 1.65% respectively [1][2] - Major technology stocks performed strongly, with Alibaba rising nearly 7%, Meituan and Baidu up over 4%, and Tencent increasing by 3.5% [2][4] Group 2 - The cryptocurrency sector faced challenges, with Bitcoin dropping below $117,000, leading to a decline in related stocks [2] - Real estate development investment in China fell by 11.2% year-on-year in the first half of the year, impacting domestic property stocks significantly [2][13] - The construction materials and cement stocks also saw declines, with major players like Jinyu Group and Anhui Conch Cement dropping over 6% and 4% respectively [11][12] Group 3 - The innovative drug sector showed strength, with companies like BeiGene and CSPC Pharmaceutical rising over 7% [7][8] - Stablecoin-related stocks performed well, with Yunfeng Financial increasing by 19.5% and Weishi Jiajie up by 11% [9][10] - The entertainment sector saw gains, with China Star Group rising over 10% and Tencent Music increasing by over 5% [15] Group 4 - Southbound funds recorded a net inflow of HKD 3.824 billion, indicating strong interest in Hong Kong stocks [18] - Analysts noted a shift in investor sentiment towards undervalued stocks, with some funds looking to capitalize on recent price corrections in major internet companies [17]

Core Viewpoint - The announcement highlights that the company has received approval from the National Medical Products Administration for the Phase III clinical trial of its self-developed product OT-802, which is indicated for the treatment of presbyopia [1] Group 1 - The product OT-802 is a hydrochloride solution of pilocarpine eye drops [1] - Preclinical studies indicate that OT-802 has a rapid onset of action and high safety profile [1] - The company plans to initiate the Phase III clinical trial of OT-802 as soon as possible [1]

Group 1 - The Hang Seng Healthcare Index (HSHCI) has risen by 2.78%, with notable increases in stocks such as Kingsoft Biotech (up 11.76%) and Eucure Biopharma (up 11.62) [3] - The Hang Seng Healthcare ETF (513060) has increased by 2.59%, with a latest price of 0.55 yuan and a turnover rate of 8.57%, amounting to a transaction volume of 734 million yuan [3] - The upcoming 85th American Diabetes Association Scientific Sessions (ADA) from June 20-23, 2025, in Chicago will feature numerous Chinese innovative drug companies, focusing on GLP-1 related innovative drug projects [3] Group 2 - The Hang Seng Healthcare ETF has a current size of 8.464 billion yuan, ranking in the top third among comparable funds [4] - The ETF has seen a net value increase of 49.67% over the past year, ranking 15th out of 119 QDII equity funds [4] - The ETF's highest monthly return since inception was 28.34%, with an average monthly return of 6.78% during rising months [4] Group 3 - The Sharpe ratio of the Hang Seng Healthcare ETF is 1.78, ranking it first among comparable funds, indicating the highest return for the same level of risk [5] - The ETF has the lowest drawdown among comparable funds, with a relative drawdown of 0.45% year-to-date [5] - The ETF's management fee is 0.50%, and the custody fee is 0.15% [5] Group 4 - The Hang Seng Healthcare Index has a current price-to-earnings ratio (PE-TTM) of 26.52, which is in the 8th percentile over the past three years, indicating a valuation lower than 92% of the time in the last three years [5] - The top ten weighted stocks in the Hang Seng Healthcare Index account for 57.52% of the index, including companies like Innovent Biologics and WuXi Biologics [5]